Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : Eli Lilly's arthritis drug fails to prevent mechanical ventilation in COVID-19 patients

04/08/2021 | 07:23am EDT

April 8 (Reuters) - Eli Lilly and Co and Incyte Corp said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized COVID-19 patients under a late-stage study.

Patients receiving baricitinib were 2.7% less likely than those receiving standard of care to progress to ventilation, which was not statistically significant, the data showed. (https://refini.tv/3t0NfHD)

Baricitinib has been granted emergency use authorization by the U.S. Food and Drug Administration in combination with remdesivir for COVID-19 patients requiring supplemental oxygen.

The study enrolled 1,525 hospitalized COVID-19 patients who received either baricitinib or placebo along with standard of care including corticosteroids and remdesivir.

Lilly will share the data from the trial with regulatory authorities in the United States, European Union and other geographies to evaluate next steps. (Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni and Devika Syamnath)


© Reuters 2021
All news about INCYTE CORPORATION
04/08INCYTE  : Eli Lilly's arthritis drug fails to prevent mechanical ventilation in ..
RE
04/08ELI LILLY AND  : Lilly, Incyte COVID-19 Drug Fails To Meet Primary Endpoint
MT
04/08INCYTE  : Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID..
RE
04/08Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint
DJ
04/06ELI LILLY AND  : Incyte Say FDA Extends Review of Dermatitis Drug
MT
04/06INCYTE  : Lilly and Incyte communicate review extension of supplemental New Drug..
PR
04/05INCYTE  : Morgan Stanley Adjusts Price Target on Incyte to $86 From $93, Maintai..
MT
04/01INCYTE  : INCY) sees Significant Insider Selling Continuing
MT
03/31INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Incyte ..
MT
03/31BRIACELL THERAPEUTICS  : to Present at the American Association for Cancer Resea..
AQ
More news
Financials (USD)
Sales 2021 2 892 M - -
Net income 2021 521 M - -
Net cash 2021 2 142 M - -
P/E ratio 2021 34,5x
Yield 2021 -
Capitalization 17 579 M 17 579 M -
EV / Sales 2021 5,34x
EV / Sales 2022 4,20x
Nbr of Employees 1 773
Free-Float 98,6%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 105,82 $
Last Close Price 79,96 $
Spread / Highest target 70,1%
Spread / Average Target 32,3%
Spread / Lowest Target -12,5%
EPS Revisions
Managers and Directors
NameTitle
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-8.07%17 579
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 993
IQVIA HOLDINGS INC.15.90%39 822
CELLTRION, INC.-13.79%37 705
SEAGEN INC.-18.44%25 900